Comparison of Neurocrine Biosciences Inc. (NBIX) and PDL BioPharma Inc. (NASDAQ:PDLI)

We will be contrasting the differences between Neurocrine Biosciences Inc. (NASDAQ:NBIX) and PDL BioPharma Inc. (NASDAQ:PDLI) as far as risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neurocrine Biosciences Inc. 451.24M 16.99 21.11M 0.18 435.91
PDL BioPharma Inc. 121.78M 4.26 62.80M -0.42 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of Neurocrine Biosciences Inc. and PDL BioPharma Inc.


Table 2 represents Neurocrine Biosciences Inc. (NASDAQ:NBIX) and PDL BioPharma Inc. (NASDAQ:PDLI)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neurocrine Biosciences Inc. 4.68% 5.1% 2.4%
PDL BioPharma Inc. -51.57% -8% -5.9%

Risk and Volatility

Neurocrine Biosciences Inc. is 86.00% more volatile than Standard and Poor’s 500 due to its 1.86 beta. PDL BioPharma Inc.’s 35.00% less volatile than Standard and Poor’s 500 which is a result of the 0.65 beta.


8.4 and 8.2 are the respective Current Ratio and a Quick Ratio of Neurocrine Biosciences Inc. Its rival PDL BioPharma Inc.’s Current and Quick Ratios are 10.9 and 10.6 respectively. PDL BioPharma Inc. has a better chance of clearing its pay short and long-term debts than Neurocrine Biosciences Inc.

Analyst Ratings

In next table is delivered Neurocrine Biosciences Inc. and PDL BioPharma Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Neurocrine Biosciences Inc. 0 3 7 2.70
PDL BioPharma Inc. 0 0 0 0.00

$112.44 is Neurocrine Biosciences Inc.’s consensus price target while its potential upside is 33.24%.

Insider and Institutional Ownership

Neurocrine Biosciences Inc. and PDL BioPharma Inc. has shares held by institutional investors as follows: 0% and 83.6%. Neurocrine Biosciences Inc.’s share held by insiders are 1.2%. Competitively, insiders own roughly 0.8% of PDL BioPharma Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Neurocrine Biosciences Inc. -2.53% -10.56% -11.62% -35.15% -6.23% 10.49%
PDL BioPharma Inc. 2.44% 18.87% 22.33% 60.85% 55.56% 30.34%

For the past year Neurocrine Biosciences Inc.’s stock price has smaller growth than PDL BioPharma Inc.


On 10 of the 12 factors Neurocrine Biosciences Inc. beats PDL BioPharma Inc.

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company’s lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women’s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson’s disease. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia. In addition, the company’s research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women’s and men’s health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL – Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson’s disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates through two segments, Income Generating Assets and Product Sales. The Income Generating Assets segment consists of royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri; and notes and other long-term receivables, royalty rights, hybrid notes/royalties receivable, and equity investments in healthcare companies. The Product Sales segment, through its equity and loan investments, manufactures, markets, and sells prescription pharmaceutical products under the Tekturna and Tekturna HCT names in the United States; and Rasilez and Rasilez HCT names internationally for the treatment of hypertension. This segment sells its products primarily to wholesalers. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.